Trial Profile
Sorafenib and Radioembolization With Sir-Spheres for the Treatment of Metastatic Ocular Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Yttrium-90
- Indications Liver metastases; Uveal melanoma
- Focus Adverse reactions; Biomarker
- 19 Apr 2018 Status changed from active, no longer recruiting to completed.
- 22 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 22 Aug 2017 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2017.